Luig Michael, Kluger Malte A, Goerke Boeren, Meyer Matthias, Nosko Anna, Yan Isabell, Scheller Jürgen, Mittrücker Hans-Willi, Rose-John Stefan, Stahl Rolf A K, Panzer Ulf, Steinmetz Oliver M
Medical Clinic III and.
Immunology Institute, Hamburg University Medical Center, Hamburg, Germany;
J Am Soc Nephrol. 2015 Jul;26(7):1597-607. doi: 10.1681/ASN.2014060620. Epub 2015 Feb 5.
IL-6 can mediate proinflammatory effects, and IL-6 receptor (IL-6R) blockade as a treatment for inflammatory diseases has entered clinical practice. However, opposing effects of IL-6 have been observed in models of GN. Although IL-6 is proinflammatory in murine lupus nephritis, protective effects have been observed for IL-6 in the nephrotoxic nephritis (NTN) model of acute crescentic GN. In light of the potential dangers of IL-6-directed treatment, we studied the mechanisms underlying the contradictory findings in GN. IL-6 can signal through the membrane-bound IL-6R, which is expressed only on hepatocytes and certain leukocytes (classic), or through the soluble IL-6R, which binds the ubiquitously expressed gp130 (alternative). Preemptive treatment of mice with anti-IL-6R or anti-IL-6 worsened NTN, whereas selective blockade of alternative IL-6 signaling by the fusion protein sgp130Fc did not. FACS analysis of mouse spleen cells revealed proinflammatory macrophages express the highest levels of IL-6Rα, and in vitro treatment with IL-6 blocked macrophage proliferation. Furthermore, proinflammatory macrophages were expanded during inflammation in IL-6(-/-) mice. Late application of anti-IL-6 after establishment of adaptive nephritogenic immunity was sufficient to aggravate NTN within 2.5 days, a period when macrophages are active. Finally, NTN was aggravated in mice with macrophage-specific impairment of IL-6 classic signaling, coincident with enhanced macrophage proliferation and accumulation in the kidney. Our data thus reveal a novel mechanism in which IL-6-mediated dampening of macrophage activation protects tissues from overshooting immune responses. This finding has important implications for potential IL-6-directed therapies and supports the careful choice of recipient patients and timing.
白细胞介素-6(IL-6)可介导促炎作用,而阻断IL-6受体(IL-6R)作为炎性疾病的一种治疗方法已进入临床实践。然而,在肾小球肾炎(GN)模型中观察到了IL-6的相反作用。虽然IL-6在小鼠狼疮性肾炎中具有促炎作用,但在急性新月体性GN的肾毒性肾炎(NTN)模型中观察到了IL-6的保护作用。鉴于针对IL-6治疗的潜在风险,我们研究了GN中这些矛盾发现背后的机制。IL-6可通过仅在肝细胞和某些白细胞上表达的膜结合IL-6R(经典途径)进行信号传导,或通过与普遍表达的gp130结合的可溶性IL-6R(替代途径)进行信号传导。用抗IL-6R或抗IL-6对小鼠进行预处理会使NTN恶化,而融合蛋白sgp130Fc对替代IL-6信号传导的选择性阻断则不会。对小鼠脾细胞进行的荧光激活细胞分选(FACS)分析显示,促炎性巨噬细胞表达的IL-6Rα水平最高,并且用IL-6进行体外处理可阻断巨噬细胞增殖。此外,在IL-6基因敲除(-/-)小鼠的炎症过程中,促炎性巨噬细胞数量增加。在适应性致肾炎免疫建立后晚期应用抗IL-6足以在2.5天内加重NTN,这是巨噬细胞活跃的时期。最后,在巨噬细胞特异性IL-6经典信号传导受损的小鼠中,NTN病情加重,同时巨噬细胞在肾脏中的增殖和积聚增强。因此,我们的数据揭示了一种新机制,即IL-6介导的巨噬细胞激活减弱可保护组织免受过度免疫反应的影响。这一发现对潜在的针对IL-6的治疗具有重要意义,并支持谨慎选择受体患者和治疗时机。